cantly higher VEGF levels in recurrent tumors (p = 0.0387) and in preoperatively irradiated tumors (p = 0.0213). Conclusion: Our data suggest a relevant role of the VEGF pathway in VS growth and therapy outcome. Therefore, targeting this pathway using antiangiogenic compounds might be beneficial for patients with sporadic VS, especially those with recurrent or irradiated tumors.
Vestibular schwannomas (VS) are rare, slow-growing neoplasms that occur as a result of increased uncontrolled proliferation of the Schwann cells of the vestibular branch of the VIIIth cranial nerve. They are typically well circumscribed and encapsulated by epineurium. Mutations of the neurofibromatosis type 2 (NF2) gene are the main cause of VS genesis in both familial and sporadic schwannomas [1] . Nevertheless, further VS growth shows diverse growth patterns. VS may grow continuously or only up to a certain size, followed by stagnation or even shrinkage [2] . Progressive growth eventually leads to displacement and/or pressure of neighboring neural struc- Vascularization and new blood vessel development are an important aspect of solid tumor growth in general [3] and have also been involved in the specific case of VS growth [4] [5] [6] [7] . Among the numerous proangiogenic growth factors, the vascular endothelial growth factor (VEGF) is considered to be a major regulator of angiogenesis. VEGF functions are largely mediated through three receptors, the VEGF receptor 1 (VEGFR-1/Flt), VEGF receptor 2 (VEGFR-2/Flk), and Neuropilin 1 (NP1) [8, 9] . VEGFR-1/Flt and VEGFR-2/Flk are expressed by Schwann cells, and VEGF has been found to act as a survival factor in these cells [10] . NP1 is a 120-to 130-kDa single-spanning transmembrane glycoprotein, initially characterized as a neuronal receptor for semaphorin, and more recently recognized as a VEGF coreceptor [9, 11] .
Besides its proangiogenic properties, VEGF also has cytoprotective activities [8, [12] [13] [14] . Tumor cell resistance to apoptosis induction due to cellular distress induced by irradiation or chemotherapy is increased after VEGF stimulation [15, 16] .
Given the promising results of the clinical application of anti-VEGF active compounds in patients with NF2-associated VS [5, 17] , a comprehensive analysis of the VEGF pathway in sporadic VS was warranted to provide a molecular basis for an antiangiogenic treatment decision.
In the present report we present our comprehensive analysis of VEGF, VEGFR-1, VEGFR-2, and NP1 expression in the tumor specimens of 182 sporadic VS patients.
Materials and Methods

Patients/Specimens
A total of 182 consecutive adult patients with solitary, sporadic, unilateral VS operated on at the Department of Otorhinolaryngology, University Medical Center of the Johannes Gutenberg University Mainz, Germany, during the years 2000-2007 were included in this study. The median age was 52 years (range 18-78); 79 patients were male and 103 female. Thirteen patients had already been treated prior to operation with stereotactic radiosurgery but still experienced tumor progress, while another 19 patients presented with recurrent tumors after operation. MRI scanning images were used for calculating the tumor diameters (d1, anteroposterior; d2, lateromedial; d3, rostrocaudal). In 24 tumors the rostrocaudal diameter was not obtainable from the MRI scanning images, and the geometrical mean of d1 and d2 was used as an estimate of this dimension. The maximum tumor diameter was used for statistical analysis. For calculation of the tumor volumes, we used the following equation, assuming an ellipsoid tumor shape: volume = 1/6 × [π] × d1 × d2 × d3. The specimens obtained in the operation room were fixed in formalin for 24 h, paraffin embedded, and used for later immunohistochemical analysis. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. The study was approved by the institutional review board and informed consent was given by the patients prior to analysis.
Tissue Microarray
Tissue microarrays were created from the resected tumor specimens. In short, paraffin-embedded tumor material was cut into 4-μm-thick sections and stained with hematoxylin/eosin. Representative areas were chosen, and biopsies of 5-mm diameter were taken from the donor block and included in recipient tissue array blocks using a precision tissue array instrument (Tissue-TEK ® Quick-Ray TM ; Sakura Finetek USA Inc., Torrance, Calif., USA). From this tissue array block 4-μm-thick sections were prepared for further immunohistochemical analysis.
Immunohistochemistry
Immunohistochemical analysis was performed using standard procedures. In brief, dewaxing and rehydration followed by blocking of endogenous peroxidase with 3% H 2 O 2 /methanol was carried out. After preincubation with 10% normal serum in 2% bovine serum albumin/phosphate-buffered saline (PBS) for 20 min to avoid unspecific binding, primary antibodies (VEGF sc-152, 1: 200; VEGFR-1/Flt-1 sc-316, 1: 150; VEGFR-2/Flk-1 sc-6251, 1: 100; NP1 sc-5307, 1: 75; Santa Cruz Biotechnology Inc., Santa Cruz, Calif., USA; Ki-67 M7240, 1: 200; DAKO A/S, Glostrup, Denmark) were overlaid overnight at 4 ° C. Slides were then incubated with goat anti-mouse or goat anti-rabbit biotinylated secondary antibody (E0433, 1: 250; E0432, 1: 250; DAKO A/S) and streptavidin/HRP (P0397, 1: 100; DAKO A/S). All washing procedures were performed in PBS. Slides were counterstained with hematoxylin. Negative controls were performed, substituting the primary antibody with PBS. Normal kidney tissue served as positive control.
Proliferative Activity
Using a light microscope we evaluated five areas of the stained sections at 400-fold magnification. At least 500 cells were evaluated per section and the mean percentage of the Ki-67 positive tumor cells was calculated.
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Statistics
The Wilcoxon rank sum test was used to assess whether differences between two groups were significant. Pearson's product moment correlation was used for statistical data evaluation, with p < 0.05 as the level of significance. Data shown are mean values ± SD. All calculations were performed using the SPSS 15.0 (SPSS, Inc., Chicago, Ill., USA). Data were not adjusted for multiple testing because of the explorative nature of the study.
Hierarchical clustering of the tumors was performed based on their expression of VEGF, VEGFR-1, VEGFR-2, NP1, proliferative index, tumor volume and diameter. The values for each parameter were normalized and the deviation from the mean was color coded (blue > mean, yellow < mean). We used k-means clustering with 3 groups in Genesis v1.75 to derive three biologically distinct groups [20] . The selection of three groups was motivated by a previous hierarchical clustering approach that allowed us to identify the largest grouping visually.
Results
In total, 182 patients (age 52 ± 10.6 years; range 18-78) were studied. Tumor volume varied between 24 and 37,679 mm 3 (mean 2,404 ± 2,329) while the maximum tumor diameter ranged between 3. We found a significant positive correlation of VEGFR-2 expression to both VEGFR-1 and NP1 expression, and a significant positive correlation of the proliferation index to the tumor volume and tumor diameter ( fig. 2 a-e) . Nonetheless, no correlation between VEGF expression and VEGFR-1, VEGFR-2 or NP1 expression was observed (data not shown). The age of the patients did not correlate with the results of the immunohistochemical quantification or with the tumor growth characteristics. Expression of neither VEGF nor its receptors correlated with the proliferation indexes or the growth characteristics of the tumors.
Interestingly, significantly increased VEGF levels were found in the groups of recurrent (p = 0.0387) and preoperatively irradiated tumors (p = 0.0213) when compared to the VEGF levels of the group of primary VS patients ( fig. 3 , 4 ) . Comparison of these three groups concerning the proliferation indexes, VEGF receptor expression, growth characteristics, and the age of the patients revealed no differences (data not shown).
Finally 
Discussion
Despite the initiation of clinical trials evaluating antiangiogenic active compounds for the therapy of familial VS, no large comprehensive analysis of the VEGF pathway in sporadic VS patients has been available until now. We here show that sporadic VS tumor growth is associated with proliferative activity and that tumor VEGF levels are correlated to tumor recurrence and radiation therapy failure.
Angiogenesis is a major prerequisite for the proliferation and progression of several neoplasms [3] . Despite the fact that VS are generally slow-growing tumors, and therefore may not need excessive vascularization for progression, a functional vascular system still remains important for further growth. VEGF is one of the most potent angiogenic factors [3, 8] and is expressed in most tumor entities [21] . Pietsch et al. [22] and Nishikawa et al. [23] ningiomas. Moreover, VEGF has been reported to act as a survival factor for Schwann cells [10] . Accordingly, upregulated VEGF expression has been previously demonstrated in VS [5, 7, [24] [25] [26] . In our present study also, all samples expressed VEGF. Moreover, we found that all of the tumors expressed VEGFR-1/Flt and VEGFR-2/Flk as well as the coreceptor NP1. Expression of VEGF and of all three receptors was identified both on tumor cells and on endothelial cells of tumor-associated vessels, which is in line with previous reports [5, 7, 26, 27] . This finding The available data concerning the proliferative activity of VS are contradictory. In a previous study, large VS exhibited enhanced proliferative activity compared with smaller lesions [28] . Similar results have also been reported by other authors describing a higher proliferative activity in large tumors [29] [30] [31] . However, these results have been contradicted by Charabi et al. [32, 33] , who found no correlation between tumor size and prolifera- tive activity. In our current analysis we found relatively low proliferative indexes, as expected for a benign neoplasm. Furthermore, we were able to identify a correlation of proliferative activity to tumor volume and tumor diameter. One possible explanation for these conflicting literature reports is that the assessment of proliferation indexes can be influenced by the point of time when the operation is performed and the tissue becomes available for analysis, since many VS do not grow continuously but can remain stable over a long period of time [2] . Niemczyk et al. [34] have reported in a study of 12 VS that the group of tumors which had been shown to grow at the time of surgical removal had a higher proliferation index than the group of stable (nongrowing) tumors. A further factor that may influence the value of the assessed Ki-67 index is the exact location of the biopsy tak- en. Szeremeta et al. [35] reported that the highest level of proliferation was found in specimens taken from the capsule of the tumor and that the proliferation activity of specimens taken from the tumor parenchyma was much lower. All these potentially confounding factors become more relevant if small sample numbers are studied. In the present study, a large number of tumors were analyzed and the tissue material used originated from biopsy specimens taken from random tumor sites (hence avoiding these potential biases), suggesting that actually impaired growth-regulating mechanisms are involved in the progression of VS. Interestingly, the recurrent tumors and the tumors treated with radiosurgery prior to operation showed a considerable elevated VEGF expression in comparison to the primary tumors. In a previous study, Uesaka et al. [27] reported an increased VEGF mRNA expression in recurrent VS, and suggested a possible involvement of VEGF in the growth or recurrence of these tumors. Our data from the present manuscript support these findings. This increased VEGF expression in the recurrent tumors may be the result of surgical trauma or the result of an intrinsic propensity of a subset of VS tumors. Since most of the recurrent VS tumors are tumor persisters, it might be assumed that in patients with tumor persistence after surgical treatment the aforementioned intrinsic propensity might accelerate the clinical/radiological manifestation of recurrence. To further clarify this issue, a comparison between the data regarding VEGF expression of the primary tumor and of the respective data of the recurrent tumor in the same patient would be necessary.
Furthermore, Uesaka et al. [27] reported that two tumors which had undergone radiation therapy before surgery also showed an increased VEGF mRNA expression. The authors hypothesized an upregulation of VEGF mRNA expression by radiation, which has been associated with rapid tumor expansion. Upregulation of VEGF by irradiation has been previously reported in a variety of neoplasms [36] [37] [38] [39] . The present data from our large-scale study support the hypothesis that irradiation of VS might lead to an upregulation of VEGF, which in the long term might be associated with progress of a residual tumor. However, a further point has to be addressed concerning the increased VEGF expression in the group of irradiated tumors. It has been previously reported that both endothelial cells of epithelial tumors and tumor cells themselves found under cellular distress might be protected by VEGF [12, 15, 16] . A similar effect of VEGF has been reported in glioblastoma cell lines [13] . In our study we found increased VEGF expression in the group of irradiated tumors. This group included tumors which have shown progress after the radiation treatment and therefore have been surgically removed. It might be possible that these tumors express high levels of VEGF per se. These increased VEGF levels might contribute to the protection of the endothelial and/or tumor cells during the radiation. Therefore, we hypothesize that a VEGF-mediated protection of VS endothelial and/or tumor cells might be a mechanism resulting in different radiation sensitivity. Consequently, the failure of radiation therapy to control VS tumors might depend on high VEGF expression levels. Whether these tumors express increased VEGF per se, or the increased VEGF expression is an epiphenomenon resulting from the radiation, remains unclear. A future in vitro study investigating further the association of radiation therapy with the expression of VEGF in VS will be the obvious extension of the present investigation.
Furthermore, cluster analysis revealed that in the group of VS patients with irradiated tumors, tumors with high proliferative indexes expressing high levels of VEGF and its receptors were more frequently observed than tumors with low proliferative activity and low VEGF and VEGF receptor expression. Similar results were observed for the recurrent tumors, suggesting that the VEGF pathway is of relevance for the proliferation of recurrent and irradiated tumors.
These data are of potential clinical relevance given that recent studies of VEGF blockade with bevacizumab in patients with NF2-associated VS showed a reduction in the volume of most VS [5, 17] . This has been attributed primarily to tumor shrinkage due to changes in intratumoral vascular permeability and subsequently due to the reduction of the intratumoral edema as well as to increased tumor cell death through the antivascular effect [5, 6, 17] .
Since sporadic VS express VEGF and its receptors, targeting this pathway may be beneficial on a clinical basis. Our cluster analysis suggests that patient selection according to molecular tumor characteristics and associated clinical features may be feasible and lead to individualized targeted therapy of VS patients. From a clinical perspective, recurrent tumors might be targeted using antiangiogenic active compounds. Moreover, if VEGFmediated VS protection through reduction of radiation sensitivity were proved, then a combination of radiation therapy and anti-VEGF treatment (especially in VS patients with high intratumoral VEGF levels) might improve treatment outcome.
